Sergio Sosa-Estani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1773657/publications.pdf

Version: 2024-02-01

41 papers

3,179 citations

236925 25 h-index 302126 39 g-index

44 all docs

44 docs citations

times ranked

44

2622 citing authors

#	Article	IF	CITATIONS
1	Prospective multicenter evaluation of real time PCR Kit prototype for early diagnosis of congenital Chagas disease. EBioMedicine, 2021, 69, 103450.	6.1	14
2	Benznidazole in Chagas disease study: do the data justify progression to phase 3? – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 1067.	9.1	2
3	New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1129-1140.	9.1	101
4	Serological reactivity against T. cruzi-derived antigens: Evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease Acta Tropica, 2021, 221, 105990.	2.0	6
5	Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2020, 14, e0008529.	3.0	17
6	Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases. Seminars in Immunopathology, 2020, 42, 231-246.	6.1	34
7	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
8	Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. PLoS Neglected Tropical Diseases, 2020, 14, e0008035.	3.0	26
9	Challenges in Chagas Disease Control Through Transmission Routes. , 2020, , 37-55.		1
10	A new patient registry for Chagas disease. PLoS Neglected Tropical Diseases, 2020, 14, e0008418.	3.0	8
11	WHF IASC Roadmap on Chagas Disease. Global Heart, 2020, 15, 26.	2.3	75
12	COVID-19: Implications for People with Chagas Disease. Global Heart, 2020, 15, 69.	2.3	39
13	Response to `letter to the editor:  Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'´. Expert Review of Anti-Infective Therapy, 2019, 17, 673-675.	4.4	3
14	Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Review of Anti-Infective Therapy, 2019, 17, 145-157.	4.4	77
15	The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America. BMJ Global Health, 2018, 3, e001069.	4.7	50
16	Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Review of Clinical Pharmacology, 2018, 11, 943-957.	3.1	84
17	Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data. International Journal of Infectious Diseases, 2018, 73, 93-101.	3.3	27
18	Congenital Transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: An Observational Prospective Study. American Journal of Tropical Medicine and Hygiene, 2018, 98, 478-485.	1.4	48

#	Article	IF	CITATIONS
19	Benznidazole and Posaconazole inÂEliminating Parasites in Asymptomatic T.ÂCruzi Carriers. Journal of the American College of Cardiology, 2017, 69, 939-947.	2.8	231
20	Comparative Study and Analytical Verification of PCR Methods for the Diagnosis of Congenital Chagas Disease. Journal of Molecular Diagnostics, 2017, 19, 673-681.	2.8	30
21	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 833-837.	3.2	67
22	Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004651.	3.0	13
23	Integrated control of Chagas disease for its elimination as public health problem - A Review. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 289-298.	1.6	29
24	Congenital Chagas disease: an update. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 363-368.	1.6	115
25	Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment. PLoS Neglected Tropical Diseases, 2015, 9, e0003697.	3.0	63
26	Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. PLoS ONE, 2015, 10, e0139363.	2.5	43
27	Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients. Journal of Molecular Diagnostics, 2015, 17, 605-615.	2.8	153
28	Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. New England Journal of Medicine, 2015, 373, 1295-1306.	27.0	807
29	Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas. PLoS Neglected Tropical Diseases, 2014, 8, e3312.	3.0	152
30	Cultural barriers to effective communication between Indigenous communities and health care providers in Northern Argentina: an anthropological contribution to Chagas disease prevention and control. International Journal for Equity in Health, 2014, 13, 6.	3.5	35
31	Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Review of Anti-Infective Therapy, 2014, 12, 479-496.	4.4	88
32	Therapy of Chagas Disease: Implications for Levels of Prevention. Journal of Tropical Medicine, 2012, 2012, 1-10.	1.7	28
33	Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women. PLoS Neglected Tropical Diseases, 2011, 5, e1250.	3.0	148
34	Early Diagnosis of Congenital Trypanosoma cruzi Infection, Using Shed Acute Phase Antigen, in Ushuaia, Tierra del Fuego, Argentina. American Journal of Tropical Medicine and Hygiene, 2010, 82, 55-59.	1.4	36
35	Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Revista Da Sociedade Brasileira De Medicina Tropical, 2009, 42, 484-487.	0.9	88
36	Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 167-180.	1.6	71

3

#	Article	IF	CITATIONS
37	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal, 2008, 156, 37-43.	2.7	183
38	Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Current Opinion in Infectious Diseases, 2006, 19, 583-587.	3.1	93
39	The translational challenge in Chagas disease drug development. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	21
40	Chagas disease control-surveillance in the Americas: the multinational initiatives and the practical impossibility of interrupting vector-borne Trypanosoma cruzi transmission. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	26
41	Critical analysis of Chagas disease treatment in different countries. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	6